No Data
Warner Pharmaceuticals: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Hunan Warrant Pharmaceutical Unit Passes GMP Compliance Inspection for Two APIs
Warner Pharmaceutical (688799.SH): Active Pharmaceutical Ingredient ipratropium bromide and dimethylpolysiloxane passed the Pharmaceutical GMP compliance inspection.
Warner Pharmaceuticals (688799.SH) announced recently that its wholly-owned subsidiary Hunan Warner Pharmaceutical Co., Ltd. has developed chiral drugs...
Warrant Pharmaceutical's Diquafosol Sodium Eye Drops Get Drug Registration Certificate
Warner Pharmaceutical (688799.SH): Diquafosol sodium eye drops have obtained the Pharmaceutical registration certificate.
On January 21, Institutional Investor announced that Warner Pharmaceutical (688799.SH) has received the Drug Registration Certificate for Diquafosol Sodium Eye Drops issued by the National Medical Products Administration. Diquafosol Sodium Eye Drops are indicated for patients with dry eye diagnosed with epithelial damage of the cornea and conjunctiva associated with tear production abnormalities.
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Shares Bounce 43% But Its Business Still Trails The Market